KR102323960B1 - 항-pd-l1 항체 및 이의 용도 - Google Patents

항-pd-l1 항체 및 이의 용도 Download PDF

Info

Publication number
KR102323960B1
KR102323960B1 KR1020197032419A KR20197032419A KR102323960B1 KR 102323960 B1 KR102323960 B1 KR 102323960B1 KR 1020197032419 A KR1020197032419 A KR 1020197032419A KR 20197032419 A KR20197032419 A KR 20197032419A KR 102323960 B1 KR102323960 B1 KR 102323960B1
Authority
KR
South Korea
Prior art keywords
ser
cancer
antibody
seq
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197032419A
Other languages
English (en)
Korean (ko)
Other versions
KR20190141169A (ko
Inventor
얀 라브로프스키
팅 쉬
게르게이 바르바쇼브
알렉세이 레픽
미하일 삼소노프
바실리 이그나티프
쇼레나 아르쿠아즈
Original Assignee
알-팜 오버씨즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알-팜 오버씨즈, 인코포레이티드 filed Critical 알-팜 오버씨즈, 인코포레이티드
Publication of KR20190141169A publication Critical patent/KR20190141169A/ko
Application granted granted Critical
Publication of KR102323960B1 publication Critical patent/KR102323960B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020197032419A 2017-04-18 2018-04-18 항-pd-l1 항체 및 이의 용도 Active KR102323960B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2017/028206 2017-04-18
US2017028206 2017-04-18
PCT/US2018/028206 WO2018195226A1 (en) 2017-04-18 2018-04-18 Anti-pd-l1 antibody and use thereof

Publications (2)

Publication Number Publication Date
KR20190141169A KR20190141169A (ko) 2019-12-23
KR102323960B1 true KR102323960B1 (ko) 2021-11-10

Family

ID=63856823

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197032419A Active KR102323960B1 (ko) 2017-04-18 2018-04-18 항-pd-l1 항체 및 이의 용도

Country Status (17)

Country Link
US (1) US20210115143A1 (https=)
EP (1) EP3612565A4 (https=)
JP (2) JP2020517239A (https=)
KR (1) KR102323960B1 (https=)
CN (1) CN110856446A (https=)
AU (1) AU2018256392B2 (https=)
BR (1) BR112019021828B1 (https=)
CA (1) CA3059447A1 (https=)
CL (1) CL2019002953A1 (https=)
CO (1) CO2019012118A2 (https=)
EA (1) EA201900443A1 (https=)
MA (1) MA50038A (https=)
MX (1) MX2019012461A (https=)
MY (1) MY199319A (https=)
PH (1) PH12019502302A1 (https=)
SG (1) SG11201909041SA (https=)
WO (1) WO2018195226A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US11046769B2 (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
CA3120096A1 (en) 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Cd25 antibodies
EP3880698A4 (en) 2018-11-14 2022-11-30 RubrYc Therapeutics, Inc. MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF
CN109929037B (zh) * 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
CN113677709B (zh) * 2019-04-11 2024-08-23 斯克里普斯抗体研究所 针对程序性细胞死亡蛋白配体-1(pd-l1)的抗体及其用途
EP3833691B1 (en) * 2019-04-26 2024-09-25 I-Mab Biopharma Co., Ltd. Human pd-l1 antibodies
WO2022006091A1 (en) * 2020-06-29 2022-01-06 Anovent Pharmaceutical (U.S.), Llc Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation
CN116178545B (zh) * 2021-09-24 2025-09-12 广东菲鹏制药股份有限公司 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105777906A (zh) * 2014-12-19 2016-07-20 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
AU2009333580B2 (en) * 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2015061668A1 (en) * 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
KR20220062143A (ko) * 2014-01-06 2022-05-13 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
CA2940242C (en) * 2014-02-20 2026-01-13 H. Lundbeck A/S Anti-acth antibodies and use thereof
CN108112254B (zh) * 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
CN117088979A (zh) * 2016-10-30 2023-11-21 上海复宏汉霖生物技术股份有限公司 抗-pd-l1抗体及变异体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105777906A (zh) * 2014-12-19 2016-07-20 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用

Also Published As

Publication number Publication date
EP3612565A4 (en) 2021-06-16
EA201900443A1 (ru) 2020-03-06
MA50038A (fr) 2020-07-08
MX2019012461A (es) 2019-12-11
PH12019502302A1 (en) 2020-09-21
JP2020517239A (ja) 2020-06-18
KR20190141169A (ko) 2019-12-23
JP2023025003A (ja) 2023-02-21
SG11201909041SA (en) 2019-11-28
BR112019021828B1 (pt) 2022-09-20
MY199319A (en) 2023-10-24
AU2018256392B2 (en) 2024-05-16
CO2019012118A2 (es) 2020-04-01
BR112019021828A2 (pt) 2020-03-24
WO2018195226A1 (en) 2018-10-25
CA3059447A1 (en) 2018-10-25
CN110856446A (zh) 2020-02-28
AU2018256392A1 (en) 2019-10-17
CL2019002953A1 (es) 2020-01-10
US20210115143A1 (en) 2021-04-22
EP3612565A1 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
KR102323960B1 (ko) 항-pd-l1 항체 및 이의 용도
US20230348602A1 (en) Novel anti-pd-1 antibodies
TWI844684B (zh) 一種抗ceacam5的單殖株抗體及其製備方法和用途
US10696745B2 (en) Anti-PD-L1 antibodies
JP2021527441A (ja) Ｃｌｄｎ１８．２を標的とする抗体、二重特異性抗体、ａｄｃ及びｃａｒならびにその使用
JP2021524268A (ja) Ｐｄ−ｌ１及びｃｄ１３７に結合する抗体分子
US12428493B2 (en) Antibodies that bind PSMA and gamma-delta T cell receptors
RS64977B1 (sr) Nova anti-pd-l1 antitela
US12509520B2 (en) Anti-CD3 and anti-CD123 bispecific antibody and use thereof
CN105777906A (zh) 抗pd-l1全人抗体及其应用
KR20200061320A (ko) 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
TW201734049A (zh) 抗－ｒｏｒ１抗體、ｒｏｒ１ ｘ ｃｄ３雙特異性抗體及使用其之方法
CN109641037A (zh) 抗psma抗体及其用途
KR20200012920A (ko) 항-cd40 항체, 이의 항원 결합 단편 및 이의 의학적 용도
KR20210104064A (ko) 항-il-27 항체 및 그의 용도
KR20230057428A (ko) 어댑터를 포함하는 약물 치료제의 개발 및 이의 용도
TW202438528A (zh) 特異性結合Ｃｌａｕｄｉｎ １８．２的抗體及其製法和應用
TW202200615A (zh) 用於治療和預防患者的crs之方法
JP2019531732A (ja) 抗ｃｄ２７抗体、その抗原結合性フラグメント、およびそのものの医学的使用
TWI835166B (zh) 靶向pd-1和/或ox40的特異性結合蛋白及其應用
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
EA044327B1 (ru) Антитело к pd-l1 и его применение
WO2025113640A1 (zh) 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途
WO2024094159A1 (zh) 靶向人源ror1的单域抗体
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191031

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200210

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210727

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20211012

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20211103

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20211103

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240514

Start annual number: 4

End annual number: 4